EUVIMEDEUVIMED entdecken
Crossref

Remission revolution; redefining CKD management from slowdown to reversal

Sepideh Hajian, Azadeh Zahedi Far

Journal of Nephropharmacology · 20.05.2026 · 15 (2) · e12855

DOI: 10.34172/npj.2026.12855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nephropharmacology, online erschienen am 20.05.2026. Verfasst von Sepideh Hajian und 1 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) has historically been managed with a traditional mindset focused solely on delaying dialysis initiation rather than restoring renal function. This entrenched paradigm is shifting due to emerging evidence suggesting that significant disease regression and clinical remission are achievable goals. Here, we examine the therapeutic landscape transforming CKD management from mere slowdown to potential reversal. We discuss on sodium glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon like peptide 1 receptor agonists alongside lifestyle modifications including dietary protein restriction and blood pressure optimization. Data indicates that early intervention targeting hemodynamic stress, systemic inflammation, and renal fibrosis can restore glomerular filtration rates (GFRs) and reduce albuminuria below nephrotic thresholds. Furthermore, clinical guidelines should evolve to prioritize remission criteria, emphasizing on aggressive early treatment windows before irreversible scarring occurs. This remission revolution necessitates a fundamental change in physician expectations and patient education, moving away from inevitable decline toward active restoration. Finally, redefining success in CKD care requires integrating these novel agents into standard practice to halt progression and actively reverse damage, offering renewed hope and improved long term outcomes for the future global CKD population while significantly reducing the economic burden associated with end stage renal disease therapy.

Zitieren

APA

Hajian, S., & Far, A. Z. (2026). Remission revolution; redefining CKD management from slowdown to reversal. Journal of Nephropharmacology, 15(2), e12855. https://doi.org/10.34172/npj.2026.12855

Vancouver

Hajian S, Far AZ. Remission revolution; redefining CKD management from slowdown to reversal. Journal of Nephropharmacology. 2026;15(2):e12855. doi:10.34172/npj.2026.12855

BibTeX
@article{Hajian2026,
  author = {Hajian, Sepideh and Far, Azadeh Zahedi},
  title = {Remission revolution; redefining CKD management from slowdown to reversal},
  journal = {Journal of Nephropharmacology},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {e12855},
  doi = {10.34172/npj.2026.12855}
}
Kostenlos starten →